Safety and immunogenicity of a Haemophilus influenzae type b polysaccharide -tetanus toxoid conjugate vaccine combined with diphtheria, tetanus and pertussis vaccines in Thai infants

Southeast Asian Journal of Tropical Medicine and Public Health

Volumn 28, Issue 1, 1997, Pages 91-98

  Chotpitayasunondh, Tawee ^a   Panpitpat, Chanatip ^b   Thisyakorn, Usa ^c   Furer, Emil ^d   Que, John U ^d   Hasler, Thomas ^d   Cryz Jr , Stanley J ^d  

^a Bangkok Children's Hospital   (Thailand)

^b Udon Thani Center Hospital   (Thailand)

^c CHULALONGKORN UNIVERSITY   (Thailand)

^d Berna Biotech AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL POLYSACCHARIDE; BACTERIUM ANTIBODY; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B POLYSACCHARIDE NEISSERIA MENINGITIDIS OUTER MEMBRANE PROTEIN CONJUGATE VACCINE; HAEMOPHILUS INFLUENZAE TYPE B POLYSACCHARIDE VACCINE; HAEMOPHILUS INFLUENZAE-TYPE B POLYSACCHARIDE-NEISSERIA MENINGITIDIS OUTER MEMBRANE PROTEIN CONJUGATE VACCINE; HAEMOPHILUS VACCINE; OUTER MEMBRANE PROTEIN; TETANUS TOXOID; VACCINE;

ARTICLE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNIZATION; IMMUNOLOGY; INFANT; MALE; MULTICENTER STUDY; NEWBORN; PREGNANCY; PRENATAL EXPOSURE; PREVENTIVE HEALTH SERVICE; RANDOMIZED CONTROLLED TRIAL; THAILAND;

ANTIBODIES, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; FEMALE; HAEMOPHILUS VACCINES; HUMANS; IMMUNIZATION PROGRAMS; IMMUNIZATION SCHEDULE; INFANT; INFANT, NEWBORN; MALE; POLYSACCHARIDES, BACTERIAL; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; TETANUS TOXOID; THAILAND; VACCINES, COMBINED; VACCINES, CONJUGATE;

EID: 0031087345     PISSN: 01251562     EISSN: 26975718     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Adams WG, Deaver KA, Cochi SL, et al. Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. JAMA 1993; 269 : 221-6.
2. Anderson P. The protective level of serum antibodies to the capsular polysacharide antigen of Haemophilus influenzae type b. J Infect Dis 1984; 149 : 1034.
3. Anonymous. Progress toward elimination of Haemophilus influenzae type b disease among infants and children United States, 1993-1994. MMWR 1995; 44 : 545-50.
4. Avandano A, Ferreccio C, Logos R, et al. Haemophilus influenzae typs b polysaccharide-tetanus protein conjugate vaccine dose not depress serologic responses to diphtheria, tetanus or pertussis antigens when coadministered in the same syringe with diphtheria-tetanus-pertussis vaccine at two, four and six months of age. Pediatr Infect Dis J 1993; 12 : 638-43.
5. Barington T, Gyhrs A, Kristensen K, et al. Opposite effects of actively and passively acquired immunity to the carrier on response of human infants to a Haemophilus influenzae type b conjugate vaccine. Infect Immun 1994; 62 : 9-14.
6. Bijlmer HA, VanAlphen L, Greenwood BM, et al. The epidemiology of Haemophilus influenzae meningitis in children under five years of age in Gambia. West Africa J Infect Dis 1990; 161 : 1210-5.
7. Bijlmer HA. World-Wide epidemiology of Haemophilus influenzae meningitis: industrailized versus non-industrailized countries. Vaccine 1991; 9 (suppl) : 5-10.
8. Black SB, Shinefield HR, Hiatt R, Polen M, Vittinghoff E. Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61,080 children. Pediatr Infect Dis J 1991; 10 : 97-104.
9. Broome CV. Epidemiology of Haemophilus influenzae type b infection in the United States. Pediatr Infect Dis J 1987; 6 : 779-82.
10. th International Congress for Infectious Diseases, 1996.
11. Chotpitayasunondh T. Bacterial menigitis in children: etiology and clinical features an 11-year review of 618 cases. Southeast Asian J Trop Med Public Health 1994; 25 : 107-15.
12. Claesson BA, Schneerson R, Robbons JB, et al. Protective levels of serum antibodies stimulated in infants by two injections of Haemophilus influenzae type b caspsular polysaccharide-tetanus toxoid conjugate. J Pediatr 1989; 114 : 97-100.
13. Decker MD, Edwards KM, Radely R, Palmer P. Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines. J Pediatr 1990; 120 : 184-9.
14. th Inter-science conference on Antimicrobial Agents and Chemotherapy (Atlanta). Washington DC: American Society for Microbiology. 1990: 96.
15. Ferreccio C, Clemens JD, Avendano A, et al. The clinical and immunologic response of Chilean infants to the clinical and Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine co-administered in the same syringe with diphtheria-tetanus toxoids-pertussis vaccine at two, four and six months of age. Pediatr Infect Dis J 1991; 10 : 764-71.
16. Fritzell B, Plotkin S. Efficacy and safety of a Haemophilus influenzae type b capsular polysaccharide-tetanus protien conjugate vaccine. J Pediatr 1992; 121 : 355-62.
17. Funkhouser A, Steinhoff M, Ward J. Haemophilus influenzae disease and immunization in developing countries. Rev Infect Dis 1991; 13 (Suppl 5) : 42-54.
18. Granoff DM, Anderson EL, Osterholm MT, et al. Differences in the immunogenicity of three Haemophilus influenzae type b conjugate vaccine in infants. J Pediatr 1992; 121 : 187-94.
19. Greenberg DP, Vadhein GM, Partride S, et al. Immunogenicity of Haemophilus influenzae type b tetanus toxoid conjugate vaccine in young infants. J Infect Dis 1994; 170 : 76-81.
20. Greenberg DP, Lieberman JM, Marcy SM, et al. Enhanced antibody responses in infants given different sequences of heterogenous Haemophilus influenzae type b conjugate vaccines. J Pediatr 1995; 126 : 206-11.
21. Kaplan SL, Lauer BA, Ward MA, et al. Immunogenicity and safety of Haemophilus influenzae type b-tetanus protein conjugate vaccine alone or mixed with diphtheria-tetanus-pertussis vaccine in infants. J Pediatr 1994; 124 : 323-7.
22. Kurikka S, Olander RM, Eskola J, et al. Passively acquired anti-tetanus and anti-Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in infancy. Pediatr Infect Dis J 1996; 15 : 530-5.
23. Lenoir AA, Granoff PD, Granoff DM. Immunogenicity of Haemophilus influenzae type b polysaccharide Neisseria meningitidis outer membrane protien conjugate vaccine in 2 to 6 month old infants. Pediatrics 1987; 80 : 283-7.
24. Lohleka S. Acute bacterial meningitis in children. Thai J Pediatr 1991; 30 : 116-20.
25. Makala PH, Takala AK, Peltola H, et al. Epimiology of invasive Haemophilus influenzae type b disease. J Infect Dis 1992; 165 (suppl) : 2-6.
26. Micheals RH, Ali O. A decline in Haemophilus influenzae type b meningitis. J Pediatr 1993; 122 : 407-9.
27. Mulholland EK, Ahonkhai VI, Greenwood BM, et al. Safety and immunogenicity of Haemophilus influenzae type b-Neisseria meningitidis Group B outer membrane protein complex conjugate vaccine mixed in the syringe with diphtheria tetanus-pertussis vaccine in young Gambian infants. Pediatr Infect Dis J 1993; 12 : 632-7.
28. Munson RS, Kabeer MH, Lenoir AA, Granoff DM. Epidemiology and prospects for prevention of disease due to Haemophilus influenzas in developing countries. Rev Infect Dis 1992; 11 (Suppl) : S588-97.
29. Paradiso PR, Hogerman DA, Madora DV, et al. Safety and immunogenicity of a combined diphtheria, tetanus, pertussis and Haemophilus influenzae type b in young infants. Pediatrics 1993; 92 : 827-32.
30. Peltola H, Kilpi T, Anttila M. Rapid disappearance of Haemophilus influenzae type b meningitis after routine childhood immunization with conjugate vaccine. Lancet 1992; 340 : 592-4.
31. Santosham M, Wolff M, Reid R, et al. The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex. N Engl J Med 1991; 324 : 1767-72.
32. Santosham M, Rivin B, Wolff M, et al. Prevention of Haemophilus influenzae type b infections in Apache and Navajo children. J Infect Dis 1992; 165 : (Suppl 1) : S144-51.
33. Shapiro ED, Ward J. The epidemiology and prevention of disease caused by Haemophilus influenzas type b. Epidemiol Rev 1991; 13 : 113-42.
34. Shinefield HR, Black S. Postlicensure surveillance for Haemophilus influenzae type b invasive disease after use of Haemophilus influenzae type b oligosaccharide CRM 197 conjugate vaccine in a large defined United State population : a four-year eight-month follow up. Pediatr Infect Dis J 1995; 14 : 978-81.
35. Vadheim CM, Greenberg DP, Eriksen E, et al. Eradication of Haemophilus influenzae type b disease in Southern California. Arch Pediatr Adolese Med 1994; 148 : 51-6.
36. Watemberg N, Dagan R, Arbelli Y, et al. Safety and immunogenicity of Haemophilus influenzae type b tetanus protein conjugate vaccine, mixed in the same syring with diphtheria-tetanus-pertussis vaccine in young infants. Pediatr Infect Dis J 1991 ; 10: 758-63.
37. Wright PF. Approaches to prevent acute bacterial meningitis in developing countries. Bull WHO 1989; 67 : 479-86.